Office of the Vice President for Research

Cornovus Pharmaceuticals

Cornovus Pharmaceuticals logo

A new target and class of agents to treat cardiac failure

Cornovus Pharmaceuticals, Inc. commenced operations in October of 2011.  The company is focused on the development of a novel cardioprotective compound, MRS2339, for the treatment of heart failure.  MRS2339 was first synthesized at the NIH and is a small molecule that stimulates cardiac myocyte P2X4 receptors, which in turn can activate physically associated eNOS without a rise in intracellular calcium.  Recent data has shown that MRS2339 also increases myocyte cGMP in a heart failure model, which likely reflects a consequence of elevated nitric oxide levels.


Bruce Liang, Founder
Glenn Mattes, CEO
Mark van Allen, COO